Credit Card Icon
Online bill pay
Calendar Icon
Book Now
Filed Paper Icon
patient portal
Doctor Icon
For Physicians
Phone Icon
(763) 416-7600

Graves Disease vs. Thyroid Eye Disease: Key Differences Explained

Posted by: Northwest Eye in graves disease ted on June 20, 2026

Graves disease and TED affect different tissues

Graves disease is an autoimmune condition in which antibodies stimulate the thyroid. Graves disease affects the thyroid, while TED inflames and swells tissues around and behind the eyes.

In Graves disease, antibodies stimulate the thyroid and cause it to make too much thyroid hormone. TED affects tissues around the eyes, including the muscles, fat, and connective tissue within the eye socket. The shared autoimmune activity explains why the conditions can occur together, but the affected tissues and the symptoms are different.

A thyroid problem does not automatically explain every eye symptom. An eye problem does not prove that you have Graves disease. You need the appropriate medical history, thyroid testing, and eye examination to sort out what is happening.

Feature Graves disease Thyroid eye disease
[Main tissue affected Thyroid gland](https://pmc.ncbi.nlm.nih.gov/articles/PMC6140607) Tissues around and behind the eyes
Main process Antibodies stimulate the thyroid to produce too much hormone Autoimmune inflammation and swelling affect the eye socket tissues
Symptoms you may notice Heat sensitivity, sweating, tremor, palpitations, weight loss, or poor sleep Dryness, redness, swelling, eyelid changes, bulging eyes, double vision, or worsening vision
Main evaluation Thyroid hormone and antibody testing, with other thyroid tests when needed Detailed eye examination, with CT or MRI in some cases
Relationship May occur with TED Usually linked with an overactive thyroid, but can occur with normal or low thyroid function

The percentage attached to Graves disease depends on the population being described. In Korea, Graves disease accounted for more than 90% of hyperthyroidism cases in one source; that figure describes Korea and should not be applied to every country or patient group.

The practical distinction is simple: Graves disease is mainly a thyroid disorder, while TED is an eye-socket disorder linked to autoimmune activity. You may have one, the other, or both, so the next step depends on your symptoms and examination findings.

TED can occur before or after thyroid problems

Thyroid eye disease can occur before or after a Graves disease diagnosis. That timing means your eye symptoms cannot be classified by thyroid history alone.

TED is usually linked with an overactive thyroid. It can also occur when thyroid function is normal or low, although that is much less common. A normal thyroid test therefore does not rule out TED, and an abnormal thyroid test does not establish that every eye change comes from TED.

If you notice new eye changes before anyone has diagnosed a thyroid condition, tell your primary clinician and arrange an appropriate eye assessment. If you already have Graves disease, mention eye symptoms even when your thyroid treatment is controlling your blood tests.

A review found that 85% of TED cases presented within 18 months before or after a Graves disease diagnosis. TED can also occur with Hashimoto’s disease, although Graves disease is the more common association.

About 10% of people with TED have normal or underactive thyroid function. This less common pattern is one reason thyroid results alone cannot settle whether eye symptoms involve TED.

A review of 57 studies involving 26,804 people with Graves disease reported TED in 40% of the overall group. The 40% estimate included different levels of eye disease, so it does not mean that every affected person had severe symptoms. The 40% figure is a prevalence estimate for the study group, not an individual diagnosis. The 40% estimate may not apply equally to every population or clinical setting. An appropriate history and eye examination are still needed because a population-level estimate cannot determine whether an individual’s eye changes are caused by TED.

TED symptoms usually last 1 to 2 years and often go away on their own. That is a general pattern, not a personal forecast.

A retrospective study followed 107 patients whose TED was inactive at the start. Seventeen of those 107 patients, or 15.9%, later experienced progression despite being classified as inactive at baseline.

That figure describes one study group rather than your individual risk. It does show why a past period of stability should not replace attention to new or changing eye symptoms. Keep track of changes in eye position, eyelid movement, double vision, and vision, then share that timeline during an evaluation.

An infographic shows TED duration and progression figures: symptoms usually last 1-2 years, one study followed 107 patients, and 15.9% later experienced progression. The figures describe a general pattern and one study group.
TED timing and stability do not eliminate the need to notice changing eye symptoms.

Know which factors raise risk

Risk factors can make Graves disease or TED more likely, but they do not confirm either diagnosis. Factors associated with Graves disease include:

  • A personal or family history of autoimmune disease.
  • Female sex.
  • Being between the ages of 30 and 60.
  • Smoking.

Smoking and abnormal thyroid function are also associated with TED. If you smoke and have Graves disease, your risk of developing TED is higher.

Use these factors as information to share with a clinician, not as a way to diagnose yourself. Tell your clinician whether you smoke, whether autoimmune conditions run in your family, and whether you have had thyroid treatment. If radioactive iodine is being considered, the presence and activity of TED risk factors should be part of that treatment discussion.

A risk factor is different from a symptom. Smoking may raise risk, but it does not mean you have TED. A family history may raise the chance of Graves disease, but it does not explain current palpitations, swelling, or vision changes by itself.

Smoking is one of the strongest modifiable risk factors for worsening TED.

Compare whole-body symptoms with eye changes

TED may cause changes in the eyes and eyelids, including:

  • Bulging eyes, also called proptosis.

  • Wider-looking or retracted eyelids.

  • Dry, watery, red, irritated, or swollen eyes.

  • Eye pain.

  • Double vision.

  • Worsening or decreased vision.

Bulging eyes and eyelid retraction are among the eye changes TED may cause. You may have dryness or watering without obvious bulging. Symptoms can vary considerably from one person to another.

The most useful comparison is the pattern of symptoms. Heat sensitivity, sweating, tremor, palpitations, and weight change suggest a whole-body thyroid effect. Eye redness, swelling, eyelid position changes, pain with eye movement, double vision, or worsening vision need attention to the tissues around the eyes.

The two patterns can overlap because Graves disease and TED can occur together. Treating thyroid symptoms does not automatically explain or resolve eye symptoms, so tell your thyroid clinician about any eye changes and tell your eye clinician about your thyroid history.

Among people with moderate-to-severe TED, visual dysfunction and facial disfigurement can substantially affect quality of life.

A comparison infographic contrasts whole-body symptoms with eye changes. Whole-body items include heat sensitivity and increased sweating, hand tremor, weight loss despite wanting to eat more, and a fast or irregular heartbeat; eye items include redness or swelling, limited movement, double or worsening vision, and eyelid changes.
Symptom patterns overlap, but thyroid effects and eye changes call for different clinical attention.

Expect thyroid tests and a detailed eye examination

Graves disease evaluation may include thyroid hormone blood tests and testing for thyroid-stimulating immunoglobulin. Clinicians may also use radioactive iodine uptake, a thyroid scan, or Doppler ultrasound when those tests help distinguish Graves disease from other causes of an overactive thyroid.

The tests answer different questions. Thyroid hormone tests show whether your thyroid function is high, low, or within the expected range. Antibody testing can support Graves disease. An uptake test, scan, or Doppler study may show how the thyroid is using iodine or how much blood is flowing through it.

Bring a list of your medicines, supplements, prior thyroid results, and symptoms to the visit. Include when the symptoms began and whether they changed after thyroid treatment.

For suspected hyperthyroidism, clinicians may start with a TSH test. If the TSH level is low, they may then check free T4 and total T3; some clinicians order all three tests at the first visit. TSH-receptor antibody testing can help distinguish Graves disease from other causes of hyperthyroidism in some patients, especially when characteristic signs are absent or radioactive iodine uptake testing is not suitable. These tests answer different questions, so the clinician chooses them based on your symptoms, examination, and thyroid history.

An uptake test measures how much iodine the thyroid takes from the bloodstream, while a thyroid scan shows how iodine is distributed through the gland.

TED evaluation includes a detailed eye examination. The examination may assess eye position, eyelid movement, eye movements, vision, the surface of the eye, and changes between visits. CT or MRI may also be used to assess the eye muscles and tissues around the eyes.

Clinicians assess TED by considering its activity, severity, eye movement, vision, changes over time, and effect on daily life. Tell the clinician whether double vision is constant or intermittent, whether it changes when you look in different directions, and whether dryness or pain interferes with sleep or work.

Severity terms describe findings rather than giving you a diagnosis to apply at home. Mild TED may include lid retraction of less than 2 mm, mild bulging, and intermittent or no double vision that can be managed with lubricating eye drops.

Moderate-to-severe TED usually includes at least 2 findings, such as lid retraction of at least 2 mm, bulging of at least 3 mm above normal, significant soft-tissue swelling, or double vision. TED is considered active when its Clinical Activity Score is at least 3 out of 7; that score includes eye pain, redness, and swelling.

Your clinician may describe these findings differently depending on the examination and the change over time. Do not use a single measurement to decide whether you need treatment.

Treatment follows the tissue and disease activity involved

Graves hyperthyroidism may be treated with antithyroid medicine, radioactive iodine, or surgery. Antithyroid medicine reduces thyroid hormone production. Radioactive iodine reduces the amount of functioning thyroid tissue, while surgery removes the thyroid tissue; the choice should be discussed with a clinician because all three treatments can be effective.

Your clinician may discuss how long to continue medicine and whether another treatment fits your thyroid findings, health, and preferences.

TED management depends on activity, severity, vision, eye movement, and the effect on daily life. Depending on those findings, care may include:

  • Lubricating eye drops for surface discomfort.
  • Selenium in selected situations.
  • Anti-inflammatory or biologic medicines.
  • Radiation.
  • Surgery.
  • Patching or prisms for double vision.

Patching or prisms can often manage TED-related double vision. If double vision persists despite these measures, eye-muscle surgery may realign the muscles. A treatment that helps one eye problem may not address the thyroid disorder, so the plan may involve more than one clinician.

Thyroid hormone levels do not always match the course or severity of TED. Treating the thyroid does not necessarily change the course of the eye disease, so eye findings need their own assessment and management plan.

If radioactive iodine is being considered, clinicians should account for TED activity and risk factors. Radioactive iodine is not recommended for active moderate-to-severe TED, and steroid prevention may be recommended in some other TED situations. After radioactive iodine therapy, thyroid testing with TSH and free T4 may be considered within 4 to 6 weeks, followed by monitoring every 2 to 3 months for up to 6 months.

TED care may involve several specialists working together. Depending on your findings, that team may include an endocrinologist and an ophthalmologist, along with other qualified clinicians involved in your care.

When TED is active and moderate-to-severe or threatens sight, antithyroid drugs are preferred for managing Graves hyperthyroidism. For mild, active TED, risk-factor control, local treatments, and selenium in selenium-deficient areas are usually sufficient.

If radioactive iodine is used for active mild TED, prophylactic corticosteroid therapy is recommended.

In the United States, teprotumumab is viewed as a first-line treatment for some thyroid eye disease patients, but its use is more limited worldwide because it costs more than glucocorticoids. Whether a biologic medicine fits depends on the clinical situation, treatment access, possible risks, and the discussion between you and your qualified clinicians.

Treatment approaches for TED can differ because clinicians do not have complete consensus on the best treatment plan.

A timeline infographic shows thyroid monitoring after radioactive iodine therapy. Thyroid testing may be considered at 4-6 weeks, monitoring may continue every 2-3 months, and follow-up may extend up to 6 months.
Post-treatment thyroid monitoring follows a schedule even while eye findings need their own assessment.

Plan around a changing timeline

TED does not follow one exact timeline. The inflammation that causes TED symptoms can last one to three years. Other clinical descriptions say TED may remain active for two years or more before inflammation subsides, while symptoms usually last 1 to 2 years and often go away on their own.

These timeframes may describe different parts of the condition. An active inflammatory phase may become quieter, but bulging eyes or double vision can persist after inflammation settles. Symptoms may also come and go during the active period.

Use the timeline to explain your experience, not to decide that a symptom is harmless. Write down when eye discomfort, swelling, eyelid changes, double vision, or vision changes began and whether each symptom is improving, stable, or worsening.

Antibodies involved in Graves disease can affect the thyroid and tissues behind the eyes because some thyroid hormone receptors are located behind the eyes. Most TED is mild, but severe TED can cause permanent cosmetic and vision changes.

Graves disease has its own treatment timeline. Most patients begin treatment with antithyroid drugs, and clinical guidelines suggest a treatment period of 12 to 18 months. Graves disease recurrence is common within 1 year of stopping an antithyroid drug; remission is defined as normal thyroid function 1 year after stopping treatment.

The length of antithyroid treatment is not the same as the length of TED. You may finish or change thyroid treatment while eye symptoms continue to need assessment. You may also have eye symptoms before thyroid treatment begins.

Graves disease relapse risk is higher with severe hyperthyroidism, a large goiter, persistently high TSH-receptor antibody levels, male sex, young age, or current smoking. These associations do not predict an individual outcome.

A quieter phase does not guarantee that every visible or functional change has disappeared. Bulging, eyelid retraction, or double vision may remain after inflammation settles. In one retrospective study, 17 of 107 patients with inactive TED, or 15.9%, experienced progression despite being classified as inactive at baseline.

That result does not predict what will happen to you. It supports keeping follow-up focused on change over time, especially if your eye position, vision, eye movement, or daily activities become different.

Timeline infographic showing three timeframes: typical TED symptoms last 1-2 years, antithyroid treatment for Graves disease is suggested for 12-18 months, and Graves disease recurrence is common within 1 year of stopping treatment. These timelines can overlap.
The length of thyroid treatment is not the same as the course of TED.

Ask what will drive the cost

There is no single typical price for Graves disease or TED care.

Hospitalizations, emergency visits, and treatment costs are major drivers of TED’s direct costs. In the United States, teprotumumab is viewed as a first-line treatment for some TED patients, but its use is more limited worldwide because it costs more than glucocorticoids. The medicine chosen and the treatment setting can therefore change the total cost.

Published cost figures describe specific study settings, not a guaranteed bill for your care. In a US study of severe TED, total charges for TED surgery exceeded $43.5 million annually, and the average charge for each surgical encounter was $21,875. Those figures describe charges for severe TED surgery in that study, not what every patient pays after insurance or other payment arrangements.

A German cross-sectional study estimated total direct TED treatment costs at $200,122,640 per year from 2005 to 2009. That estimate covered the total German population during that period, so it is not a current US price or a personal cost estimate.

Before treatment, ask focused questions about the financial side of the plan:

  • Which condition is each proposed treatment intended to manage?
  • Is the quoted amount a charge, an allowed amount, or your expected out-of-pocket cost?
  • Will the plan involve medicine, imaging, surgery, hospital care, or more than one specialist?
  • Which parts of care may occur more than once?
  • How could the plan change if symptoms improve, persist, or worsen?

These questions help you separate the medical decision from the financial estimate. A treatment choice should not be based on a cost figure taken from a different country, year, condition, or severity level.

Arrange the right eye evaluation for warning signs

Seek urgent ophthalmology care for suspected optic-nerve involvement, corneal breakdown, a displaced globe, or new double vision. These findings can signal an eye problem that needs prompt assessment rather than a routine discussion at a later time.

Sight-threatening TED can compress the optic nerve and cause reduced vision, reduced color vision, or reduced contrast sensitivity. This occurs in less than 5% of people with typical TED, but the uncommon nature of the problem should not delay care when those changes appear.

Arrange an ophthalmology evaluation for worsening eye changes, an uncertain diagnosis, TED with normal thyroid function, clearly one-sided or very unequal disease, or a major effect on daily life. These situations can be difficult to judge from symptoms alone.

EUGOGO guidance recommends early referral to specialized centers for most people with TED. If you have a possible thyroid-related eye problem, bring your thyroid test results, treatment history, medication list, and a record of changes in your eyes or vision.

Use the timing of your symptoms to describe the problem clearly:

  • Note whether double vision is new, intermittent, or constant.
  • Record any change in vision, color vision, or contrast.
  • Describe new swelling, redness, pain, eyelid changes, or eye displacement.
  • Explain whether the change affects driving, reading, work, sleep, or other daily activities.

This information helps the ophthalmology team assess activity, severity, movement, vision, change over time, and daily impact.

Regular evaluations by a specialist can compare precise measurements of eye-muscle movement and visual function from one visit to the next. A subtle change may indicate improvement or worsening.

Book an appointment to discuss your symptoms

Graves disease and TED can be connected without being the same condition. Graves disease mainly affects the thyroid, while TED affects tissues around the eyes, so thyroid testing and eye evaluation answer different questions.

If eye symptoms or thyroid concerns are affecting you, an eye exam at Northwest Eye in Minnetonka is a practical place to discuss your symptom timeline, testing questions, and the type of evaluation you may need.

Questions to ask about Graves disease and TED

Can a normal thyroid test rule out thyroid eye disease?

No. Thyroid eye disease can occur when thyroid function is normal or low, although that is less common. If you have new eye swelling, bulging, eyelid changes, double vision, or worsening vision, arrange an eye evaluation even if your thyroid blood tests are normal.

Does treating Graves disease also treat the eye symptoms?

Not necessarily. Thyroid treatment may sometimes help Graves-related eye disease, but eye symptoms often need their own assessment and treatment. An ophthalmologist can evaluate eye movement, vision, eyelid position, and changes over time while your thyroid clinician manages hormone levels.

What should I bring to an evaluation for possible Graves disease or TED?

Bring your medication and supplement list, thyroid test results, treatment history, and a timeline of symptom changes. Note whether double vision is intermittent or constant and whether vision, eye position, pain, swelling, or daily activities have changed. These details help clinicians plan the appropriate evaluation.

Are published thyroid eye disease costs the same as my personal bill?

No. Published figures may describe charges for a specific country, year, treatment, or severity level rather than your out-of-pocket cost. Ask whether an estimate is a charge, allowed amount, or expected payment, and whether it includes imaging, medicines, surgery, hospital care, or multiple specialists.


locations

Serving Our Community

With six locations throughout the Twin Cities metro area, Northwest Eye is among the largest eye care providers in the Midwest. Be Eye Wise and schedule a general eye exam or a specific service consultation today. We have optical  at the following offices:  Golden Valley, Minnetonka, Maple Grove, St. Anthony, and Wayzata, MN.

8501 Golden Valley Rd.,
Suite 100 & 200
Golden Valley, MN 55427
Additional Golden Valley Information
12501 Whitewater Drive, Suite 110
Minnetonka, MN 55343
Additional Minnetonka Clinic (Crosstown) Information
12000 Elm Creek Blvd N., Suite 100
Maple Grove, MN 55369
Additional Maple Grove Information
2601 39th Ave NE., Suite 1
St. Anthony, MN 55421
Additional St. Anthony Information
1903 E. Wayzata Blvd., Suite 110
Wayzata, MN 55391

Additional Wayzata Information
7125 Tamarack Rd, Suite 150,
Woodbury, MN 55125
Additional Woodbury Information
11091 Ulysses St NE., Suite 400
Blaine, MN 55434
Additional Blaine Surgery Center Information
9801 Dupont Ave S., Suite 100
Bloomington, MN 55431
Additional Bloomington Surgery Center Information
12501 Whitewater Drive
Suite 320
Minnetonka, MN 55343
Additional Crosstown Surgery Center Information
10709 Wayzata Blvd., Suites 100 & 120
Minnetonka, MN 55305
Additional Minnetonka Surgery Center Information